Canbud's Subsidiary, Empathy Plant Co. Begins Build-Out of Sales Team
Toronto, Ontario--(Newsfile Corp. - May 4, 2021) - Canbud Distribution Corporation (CSE: CBDX) (FSE: CD0) ("Canbud" or the "Corporation") announces its subsidiary, Empathy Plant Co. has begun to build out an experienced sales team to lead the expansion of its plant-based product lines.
With the Complete Plant Protein production order being executed, Empathy Plant Co. now focuses on onboarding highly experienced salespeople that can lead the Corporation into new markets and drive awareness for its innovative brand. Headed by 30-year nutraceutical industry veteran, Ryan Herniman, the remote working structure lends well to the current COVID-19 operating environment. Mr.Herniman's brick and mortar contacts and operational experience will be invaluable as Empathy Plant Co. pushes to scale various product lines across North America's health and wellness space.
This next phase of the team buildout not only supports the omnichannel sales strategy, but also allows for an infrastructure which will streamline the onboarding of M&A targets while supporting inhouse brand launches.
Steve Singh, CEO comments:
As we continue to push to commercialization, assembling industry veterans is going to greatly accelerate the Canbud vision in the health and wellness space. Empathy Plant Co. is already gaining market awareness and quality human equity will help drive shareholder equity.
Canbud Distribution Corporation is a science and technology health and wellness company that encompasses plant based, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) verticals.
Notice Regarding Forward-Looking Information
This news release is not an offer to sell, or a solicitation of an offer to buy or sell, any securities of the Corporation and may not be relied upon in connection with the purchase or sale of any such security.
This news release contains "forward-looking information" within the meaning of Canadian securities legislation. The forward-looking information contained in this news release represents the expectations of the Corporation as of the date of this news release and, accordingly, is subject to change after such date. Forward-looking information includes information including statements with respect to the future exploration performance of the Corporation. Forward-looking information is based on, among other things, opinions, assumptions, estimates and analyses that, while considered reasonable by the Corporation at the date the forward-looking information is provided, are inherently subject to significant risks, uncertainties, contingencies, and other factors that may cause actual results and events to be materially different from those expressed or implied by the forward-looking information. The risks, uncertainties, contingencies and other factors that may cause actual results to differ materially from those expressed or implied by the forward-looking information may include, but are not limited to (i) adverse market conditions; (ii) risks inherent in the CBD, psychedelics and vegan protein industries in general or (iii) risks generally associated with the Corporation's business, as described in the Corporation's public filings on SEDAR, which readers are encouraged to review in detail prior to any transaction involving the securities of the Corporation. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Corporation does not intend to update these forward-looking statements. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.